On October 22, 2024, we acquired privately-held Opus Genetics Inc., a clinical-stage gene therapy company focused on IRDs, in ...

The first clinical trial of a generative AI therapy bot suggests it was as effective as human therapy for people with ...

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...

Keros plans on engaging with regulatory authorities, starting in the third quarter of 2025. Subject to the outcome of these regulatory interactions, Keros expects to initiate a Phase 2 clinical trial ...

IgniteData is committed to scaling its EHR-to-EDC automation across global research sites, further advancing clinical trial innovation. Insights gained from each deployment will continue to refine and ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

The Lancet research papers build on the WHO’s Guidance for best practices in clinical trials released in September 2024.

American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...

European clinicians and scientists are to receive £5.5m in funding to form a world-leading research team tasked with making ...